< Key Hightlight >

MARKET OUTLOOK 

As per Triton Market Research’s report, the North America Alzheimer’s disease therapeutics and diagnostics market is anticipated to develop with a CAGR of 5.41% in terms of revenue, during the forecast years from 2021 to 2028. The United States and Canada together form the market in this region.

The United States is the largest player in the AD therapeutics and diagnostics market. As per the National Institutes of Health (NIH), approximately 5.8 million Americans were reported to be affected by Alzheimer’s disease in 2020. Of these, an estimated 5.6 million people were aged 65 and above. 

Data from the US Census Bureau suggests that, the population of Americans aged 65 and above is estimated to rise to 88 million individuals by 2050. As the number of people in the country aged 65 and over continues to increase, the cases of Alzheimer’s are also expected to spiral. This will benefit the growth of the US market.

The United States’ Food and Drug Administration has approved four molecules for Alzheimer’s disease treatment, namely, galantamine, rivastigmine, memantine, and donepezil. Also, a combination drug containing donepezil and memantine is widely available in the market. According to the National Clinical Trials Registry (NCT), currently, 144 active clinical trials are under development in the US for Alzheimer’s disease across different phases.

COMPETITIVE OUTLOOK

The dominant players in the Alzheimer’s disease therapeutics and diagnostics market are Luye Pharma Group, Siemens Healthineers AG, Amarantus Bioscience Holdings Inc, GE Healthcare, Cognoptix Inc, Baxter International Inc, Johnson & Johnson, Eisai Co Ltd, Teva Pharmaceutical Industries Limited, and Merck & Co Inc.